Literature DB >> 17185296

Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species.

Charalampos Antachopoulos1, Joseph Meletiadis, Tin Sein, Emmanuel Roilides, Thomas J Walsh.   

Abstract

OBJECTIVES: To develop and evaluate a new method for rapid susceptibility testing of Aspergillus spp. based on early metabolic signalling of high-inoculum biomass.
METHODS: Susceptibility to amphotericin B and voriconazole was studied in 39 clinical isolates of Aspergillus spp. (16 Aspergillus fumigatus, 11 Aspergillus flavus, 12 Aspergillus terreus). At 6 or 8 h after inoculation for A. fumigatus and A. flavus, and at 8 or 12 h after inoculation for A. terreus, 100 microg/mL of the tetrazolium salt XTT and 25 microM menadione were added and absorbance measured at 450 nm after 2 h of incubation at 37 degrees C. Inocula used were 10(6) conidia/mL for A. fumigatus and A. terreus and 10(5) conidia/mL for A. flavus, as lower inocula exhibited very low metabolic activity at these time points. Data were analysed with the sigmoid E(max) model and compared with visual (lowest drug concentration showing no growth) and spectrophotometric MIC determination at 48 h (CLSI M38-A method).
RESULTS: The E(max) model described well the concentration-effect relationship for early metabolic activity and 48 h fungal biomass (median r(2): 0.97 and 0.93, respectively). Use of the model allowed characterization and quantification of species- and drug-related differences in pharmacological inhibition of early metabolic activity as well as calculation of appropriate cutoff levels for MIC determination with the XTT assay. Using these cutoff levels, for A. fumigatus and A. flavus at both time points (6 and 8 h) and for A. terreus at 12 h, the agreement (+/- one dilution) of the XTT assay with the CLSI method was 91-100% and its reproducibility was 97-100%.
CONCLUSIONS: This newly developed high-inoculum-based method provides rapid and reproducible MIC determinations for Aspergillus spp.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185296     DOI: 10.1093/jac/dkl488

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.

Authors:  Eleftheria Mavridou; Joseph Meletiadis; Antony Rijs; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

2.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Rafal Al-Saigh; Maria Siopi; Nikolaos Siafakas; Aristea Velegraki; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

4.  Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.

Authors:  Ricardo Araujo; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

5.  Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes.

Authors:  Atef S Shehata; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  J Clin Microbiol       Date:  2008-10-01       Impact factor: 5.948

6.  In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.

Authors:  R Al-Saigh; A Elefanti; A Velegraki; L Zerva; J Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

7.  Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis.

Authors:  S Deng; W Pan; W Liao; G S de Hoog; A H G Gerrits van den Ende; R G Vitale; H Rafati; M Ilkit; A H Van der Lee; A J M M Rijs; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.

Authors:  Seyedmojtaba Seyedmousavi; Joseph Meletiadis; Willem J G Melchers; Antonius J M M Rijs; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

9.  Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

Review 10.  The Gibberellin Producer Fusarium fujikuroi: Methods and Technologies in the Current Toolkit.

Authors:  Yu-Ke Cen; Jian-Guang Lin; You-Liang Wang; Jun-You Wang; Zhi-Qiang Liu; Yu-Guo Zheng
Journal:  Front Bioeng Biotechnol       Date:  2020-03-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.